1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Patient Monitoring Device Market Trends
  5. > United States Cardiac Rhythm Management Market Outlook to 2020

United States Cardiac Rhythm Management Market Outlook to 2020

Summary

GlobalData’s new report, "United States Cardiac Rhythm Management Market Outlook to 2020", provides key market data on the United States Cardiac Rhythm Management Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Cardiac Resynchronisation Therapy (Defibrillators and Pacemakers), Implantable Cardioverter Defibrillators, Implantable Loop Recorders and Pacemakers.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiac Rhythm Management Market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size for Cardiac Rhythm Management Devices categories - Cardiac Resynchronisation Therapy, Implantable Cardioverter Defibrillators, Implantable Loop Recorders and Pacemakers.
- Annualized market revenue (USD million), volume (units) and average selling price ($) data for the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
- 2012 company shares and distribution shares data for the market category.
- Global corporate-level profiles of key companies operating within the United States Cardiac Rhythm Management Devices market.
- Key players covered include Medtronic, Inc., St. Jude Medical, Inc., Boston Scientific Corporation and BIOTRONIK SE & Co. KG.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Table Of Contents

United States Cardiac Rhythm Management Market Outlook to 2020
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 What Is This Report About? 9
2.2 Cardiac Rhythm Management Market Segmentation 9
2.3 Definitions of Markets Covered in the Report 10
3 Cardiac Rhythm Management Market, United States 12
3.1 Cardiac Rhythm Management Market, United States, Revenue ($m), 2005-2012 12
3.2 Cardiac Rhythm Management Market, United States, Revenue ($m), 2012-2020 14
3.2.1 Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), by Segment, 2005-2012 16
3.2.2 Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), by Segment, 2005-2012 18
3.2.3 Pacemakers Market, United States, Revenue ($m), by Segment, 2005-2012 20
3.2.4 Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), by Segment, 2012-2020 22
3.2.5 Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), by Segment, 2012-2020 24
3.2.6 Pacemakers Market, United States, Revenue ($m), by Segment, 2012-2020 26
3.3 Cardiac Rhythm Management Market, United States, Volume (Units), 2005-2012 28
3.4 Cardiac Rhythm Management Market, United States, Volume (Units), 2012-2020 30
3.4.1 Cardiac Resynchronisation Therapy Market, United States, Volume (Units), by Segment, 2005-2012 32
3.4.2 Implantable Cardioverter Defibrillators Market, United States, Volume (Units), by Segment, 2005-2012 34
3.4.3 Pacemakers Market, United States, Volume (Units), by Segment, 2005-2012 36
3.4.4 Cardiac Resynchronisation Therapy Market, United States, Volume (Units), by Segment, 2012-2020 38
3.4.5 Implantable Cardioverter Defibrillators Market, United States, Volume (Units), by Segment, 2012-2020 40
3.4.6 Pacemakers Market, United States, Volume (Units), by Segment, 2012-2020 42
3.5 Cardiac Rhythm Management Market, United States, Average Price ($), 2005-2020 44
3.6 Cardiac Rhythm Management Market, United States, Distribution Share by Revenue ($m), 2011-2012 46
3.7 Cardiac Rhythm Management Market, United States, Company Share by Revenue ($m), 2011-2012 47
4 Overview of Key Companies in United States, Cardiac Rhythm Management Market 49
4.1 Medtronic, Inc. 49
4.1.1 Company Overview 49
4.2 St. Jude Medical, Inc. 49
4.2.1 Company Overview 49
4.3 Boston Scientific Corporation 49
4.3.1 Company Overview 49
4.4 Biotronik SE and Co. KG 50
4.4.1 Company Overview 50
4.5 Sorin S.p.A. 50
4.5.1 Company Overview 50
5 Cardiac Rhythm Management Market Pipeline Products 51
6 Financial Deals Landscape 52
6.1 Acquisition 52
6.1.1 Merit Medical Completes Acquisition Of Thomas Medical From GE Healthcare For Up To US$167 Million 52
6.2 Debt Offerings 54
6.2.1 Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million 54
6.2.2 Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million 56
6.2.3 Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million 58
6.2.4 Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million 60
6.2.5 Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 62
6.2.6 Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 64
6.2.7 Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 66
6.3 Equity Offerings 68
6.3.1 Stereotaxis Files Registration Statement For Public Offering Of Securities For Up To US$75 Million 68
6.3.2 Stereotaxis Completes Rights Offering Of Shares For US$10.2 Million 69
6.4 Partnerships 70
6.4.1 ZOLL Medical Enters Into Licensing Agreement With Inovise Medical 70
6.5 Venture Financing 71
6.5.1 Rijuven Raises US$0.3 Million In Venture Financing 71
6.5.2 iRhythm Technologies Raises US$16 Million In Series D Financing 72
6.5.3 iRhythm Technologies Raises US$3.5 Million In Venture Financing 74
7 Recent Developments 76
7.1 Corporate Communications 76
7.1.1 Apr 16, 2014: Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network 76
7.1.2 Apr 08, 2014: Ventripoint Corporate Update and Resignation of Director 76
7.1.3 Feb 18, 2014: SurModics Announces Changes to Board of Directors 77
7.1.4 Feb 14, 2014: Stereotaxis Appoints William C. Mills III to Chief Executive Officer 78
7.1.5 Jan 06, 2014: Catalyst Pharmaceutical Partners Reports Successful Completion of Type B Breakthrough Therapy Meeting With FDA on Firdapse Tablets Development Program 79
7.1.6 Dec 05, 2013: Anxious Patient Group Calls on NICE to Approve Only Drug Treatment for Ultra-Rare Disease 80
7.1.7 Nov 04, 2013: Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis 82
7.1.8 Sep 25, 2013: Accellent Announces the Promotion of Jeremy Friedman to President and Chief Operating Officer for the Cardio and Vascular Business and the Appointment of Richard Johnson as Interim CFO 82
7.1.9 Sep 20, 2013: SurModics Announces Board Changes 83
7.1.10 Sep 16, 2013: Arena Pharmaceuticals Provides Update as Eisai's Launch of BELVIQ CIV Enters Consumer Phase 83
7.1.11 Aug 19, 2013: Orthofix Receives Expected NASDAQ Notice Related to Late Filing of Form 10-Q 84
7.1.12 Aug 16, 2013: Stereotaxis Announces Listing Transfer to NASDAQ Capital Market 84
7.1.13 Aug 02, 2013: China CDC Enters Into RandD Agreement With Aeras Global For TB Vaccine 84
7.1.14 Jul 23, 2013: Dean Schauer, Executive Vice President, Cardio and Vascular Group, Announces Resignation 86
7.1.15 Jul 02, 2013: InSite Vision Receives Notice of Allowance from USPTO for Patent on DuraSite 2 Ophthalmic Drug Delivery System 86
7.2 Financial Announcements 87
7.2.1 May 06, 2014: Stereotaxis Reports 2014 First Quarter Financial Results 87
7.2.2 May 01, 2014: SurModics Reports Second Quarter Fiscal 2014 Results 88
7.2.3 Apr 22, 2014: Bard Announces First Quarter Results 90
7.2.4 Feb 25, 2014: Stereotaxis Reports 2013 Fourth Quarter and Full Year Financial Results 90
7.2.5 Feb 18, 2014: Medtronic Reports Third Quarter Earnings 92
7.2.6 Jan 30, 2014: Bard Announces Fourth Quarter Results 94
7.2.7 Jan 30, 2014: SurModics Reports First Quarter Fiscal 2014 Results 94
7.2.8 Dec 11, 2013: Bard Declares Quarterly Dividend 96
7.2.9 Nov 19, 2013: Medtronic Reports Second Quarter Earnings 96
7.2.10 Nov 14, 2013: Stereotaxis Reports Third Quarter 2013 Financial Results 98
7.2.11 Nov 11, 2013: Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014 100
7.2.12 Nov 07, 2013: Accellent Announces Third Quarter 2013 Results 100
7.2.13 Nov 05, 2013: SurModics Reports Fourth Quarter and Full Year 2013 Results 101
7.2.14 Oct 29, 2013: SurModics to Webcast Fourth Quarter and Fiscal Year 2013 Earnings Conference Call on November 5 103
7.2.15 Oct 23, 2013: Stereotaxis Announces Preliminary Third Quarter 2013 Financial Results in Preparation for Rights Offering 103
7.2.16 Oct 22, 2013: Bard Announces Third Quarter Results 104
7.2.17 Oct 09, 2013: Bard Declares Quarterly Dividend 104
7.2.18 Oct 01, 2013: Bard to Host Earnings Conference Call on October 22, 2013 104
7.2.19 Aug 20, 2013: Medtronic Reports First Quarter Earnings 105
7.2.20 Aug 13, 2013: Accellent Announces Second Quarter 2013 Results 106
7.2.21 Aug 12, 2013: Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014 107
7.2.22 Aug 08, 2013: Stereotaxis Reports Second Quarter 2013 Financial Results; Announces Capital Transactions 108
7.2.23 Aug 06, 2013: Accellent Announces Timing of Second Quarter 2013 Earnings Release and Conference Call 110
7.2.24 Jul 31, 2013: SurModics Reports Third Quarter Fiscal 2013 Results 110
7.2.25 Jul 24, 2013: Bard Announces Second Quarter Results 112
7.2.26 Jul 23, 2013: SurModics to Webcast Third Quarter 2013 Earnings Conference Call on July 31 113
7.2.27 May 21, 2013: Medtronic Reports Revenue Of $16.6 Billion In Fiscal 2013 113
7.2.28 May 14, 2013: Accellent Reports Revenue Of $120.8m In Q1 2013 115
7.2.29 May 13, 2013: Stereotaxis Reports Revenue Of $8.4m In Q1 2013 115
7.3 Government and Public Interest 116
7.3.1 Jan 06, 2014: Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference 116
7.3.2 Jan 06, 2014: Bard to Host Earnings Conference Call on January 30, 2014 116
7.3.3 Dec 20, 2013: Bard to Present at J.P. Morgan Healthcare Conference 116
7.3.4 Dec 06, 2013: Stereotaxis to Present at Oppenheimer 24th Annual Healthcare Conference in New York on December 11, 2013 117
7.3.5 Dec 04, 2013: SurModics to Present at Oppenheimer Healthcare Conference 117
7.3.6 Dec 04, 2013: Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference 117
7.3.7 Nov 26, 2013: SurModics to Present at Piper Jaffray Healthcare Conference 117
7.3.8 Nov 26, 2013: Medtronic EVP and President Mike Coyle to Speak at Piper Jaffray Healthcare Conference 117
7.3.9 Nov 20, 2013: Bard to Present at Piper Jaffray Healthcare Conference 117
7.3.10 Nov 12, 2013: SurModics to Present at Canaccord Genuity Medical Technology and Diagnostics Conference 118
7.3.11 Oct 29, 2013: Bard to Present at Credit Suisse Healthcare Conference 118
7.3.12 Sep 06, 2013: Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference 118
7.3.13 Sep 03, 2013: Bard to Host Conference Call on September 4, 2013 118
7.3.14 Aug 27, 2013: SurModics to Present at CL King's Best Ideas Conference 118
7.3.15 Aug 20, 2013: Bard to Present at Morgan Stanley Global Healthcare Conference 118
7.3.16 May 21, 2013: SurModics to Present at the Jefferies Global Healthcare Conference 119
7.4 Legal And Regulatory 119
7.4.1 Apr 11, 2014: Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve 119
7.4.2 Mar 12, 2014: Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test 119
7.4.3 Jan 22, 2014: Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures 120
7.4.4 Oct 19, 2013: Medtronic Statement on Medical Device Security 121
7.4.5 Aug 16, 2013: Glancy Binkow and Goldberg Announces Class Action Lawsuit Against Orthofix International 121
7.4.6 Aug 01, 2013: Medtronic Notifies More Than 2,700 Patients Of Lost Records 121
7.4.7 Jul 01, 2013: Bronstein, Gewirtz and Grossman, LLC Announces that a Securities Class Action has been Filed Against Medtronic, Inc. 122
7.5 Other Significant Developments 122
7.5.1 Apr 16, 2014: Bard Declares Quarterly Dividend 122
7.5.2 Feb 13, 2014: Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014 122
7.5.3 Jan 28, 2014: Medtronic Relocates Its Regional Headquarters to Dubai 123
7.5.4 Jan 08, 2014: BIOTRONIK Devices and Leads, including latest DX System Technology, Now Available for Veterans Affairs Clients 124
7.5.5 Dec 04, 2013: Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles 124
7.5.6 Nov 27, 2013: Stereotaxis announces results of rights offering 125
7.5.7 Sep 03, 2013: SurModics Announces Organizational Changes 126
7.5.8 Aug 22, 2013: Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014 126
7.5.9 Jul 22, 2013: SurModics to Present at the InvestMNt Conference 127
7.6 Product News 127
7.6.1 Feb 13, 2014: New Data Support Use of iRhythm's ZIO Service to Identify Cardiac Arrhythmias in Stroke and TIA Patients 127
7.6.2 Jan 27, 2014: Laerdal Medical and Wolters Kluwer Health Introduce Virtual Simulation Learning Tool for Nursing Students 128
7.6.3 Jan 02, 2014: ZIO Service Identifies Significantly More Cardiac Arrhythmias Than the Traditional Holter Monitor, According to Study Published Online in the American Journal of Medicine 129
7.6.4 Dec 20, 2013: First-in-Man Implantation of CARMAT's Bioprosthetic Artificial Heart 129
7.6.5 Nov 15, 2013: FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall 130
7.6.6 Oct 02, 2013: Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation 131
7.6.7 Jun 25, 2013: nContact Continues To Expand Intellectual Property Portfolio For Its Multidisciplinary Approach For Treatment Of Cardiac Arrhythmias 131
7.7 Strategy And Business Planning 132
7.7.1 Sep 17, 2013: Medtronic Opens New Customer Innovation Centre in Galway, Ireland 132
7.7.2 Sep 02, 2013: Medtronic announces formation of hospital solutions business aimed at driving efficiencies 133
7.7.3 Aug 29, 2013: Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation 134
8 Appendix 135
8.1 Research Methodology 136
8.1.1 Coverage 136
8.1.2 Secondary Research 136
8.1.3 Primary Research 137
8.1.4 Market Modeling and Forecasting 138
8.1.5 Company Share Analysis 141
8.1.6 Distribution Share Analysis 142
8.2 Expert Panel 142
8.3 GlobalData Consulting 143
8.4 Contact Us 143
8.5 Disclaimer 143

1.1 List of Tables
Table 1: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 13
Table 2: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 15
Table 3: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 17
Table 4: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 19
Table 5: Pacemakers Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 21
Table 6: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 23
Table 7: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 25
Table 8: Pacemakers Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 27
Table 9: Cardiac Rhythm Management Market, United States, Volume (Units), Historic, 2005-2012 29
Table 10: Cardiac Rhythm Management Market, United States, Volume (Units), Forecast, 2012-2020 31
Table 11: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Historic, 2005-2012 33
Table 12: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Historic, 2005-2012 35
Table 13: Pacemakers Market, United States, Volume (Units), Historic, 2005-2012 37
Table 14: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Forecast, 2012-2020 39
Table 15: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Forecast, 2012-2020 41
Table 16: Pacemakers Market, United States, Volume (Units), Forecast, 2012-2020 43
Table 17: Cardiac Rhythm Management Market, United States, Average Price ($), Historic, 2005-2012 44
Table 18: Cardiac Rhythm Management Market, United States, Average Price ($), Forecast, 2012-2020 45
Table 19: Cardiac Rhythm Management Market, United States, Distribution Share by Revenue ($m), USD Constant, 2011-2012 46
Table 20: Cardiac Rhythm Management Market, United States, Company Share by Revenue ($m), USD Constant, 2011-2012 48
Table 21: Cardiac Rhythm Management Market Pipeline Products 51
Table 22: Merit Medical Completes Acquisition Of Thomas Medical From GE Healthcare For Up To US$167 Million 52
Table 23: Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million 54
Table 24: Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million 56
Table 25: Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million 58
Table 26: Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million 60
Table 27: Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 62
Table 28: Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 64
Table 29: Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 66
Table 30: Stereotaxis Files Registration Statement For Public Offering Of Securities For Up To US$75 Million 68
Table 31: Stereotaxis Completes Rights Offering Of Shares For US$10.2 Million 69
Table 32: ZOLL Medical Enters Into Licensing Agreement With Inovise Medical 70
Table 33: Rijuven Raises US$0.3 Million In Venture Financing 71
Table 34: iRhythm Technologies Raises US$16 Million In Series D Financing 72
Table 35: iRhythm Technologies Raises US$3.5 Million In Venture Financing 74
Table 36 Total Number of Primary Research Participants, Cardiovascular Devices Market, by Country 138

1.2 List of Figures
Figure 1: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 12
Figure 2: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 14
Figure 3: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 16
Figure 4: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 18
Figure 5: Pacemakers Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 20
Figure 6: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 22
Figure 7: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 24
Figure 8: Pacemakers Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 26
Figure 9: Cardiac Rhythm Management Market, United States, Volume (Units), Historic, 2005-2012 28
Figure 10: Cardiac Rhythm Management Market, United States, Volume (Units), Forecast, 2012-2020 30
Figure 11: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Historic, 2005-2012 32
Figure 12: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Historic, 2005-2012 34
Figure 13: Pacemakers Market, United States, Volume (Units), Historic, 2005-2012 36
Figure 14: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Forecast, 2012-2020 38
Figure 15: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Forecast, 2012-2020 40
Figure 16: Pacemakers Market, United States, Volume (Units), Forecast, 2012-2020 42
Figure 17: Cardiac Rhythm Management Market, United States, Company Share (%), 2012 47
Figure 18: GlobalData Epidemiology-Based Forecasting Model 140
Figure 19: GlobalData Capital Equipment-Based Forecasting Model 141
Figure 20: Primary Interviews by Participant Type (%) 142

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Defibrillators Market by Product and External, End User - Global Forecasts to 2021

Defibrillators Market by Product and External, End User - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global defibrillators market is expected to reach USD 14.21 billion by 2021 from USD 10.01 billion in 2016, at a CAGR of 7.3% between 2016 and 2021. The defibrillators market is broadly segmented into ...

Cardiac Monitoring & Cardiac Rhythm Management Devices Market - Global Forecast to 2021

Cardiac Monitoring & Cardiac Rhythm Management Devices Market - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global CM & CRM devices market is projected to reach USD 28 billion by 2021 from USD 22.19 billion in 2016, at a CAGR of 4.8% from 2016 to 2021. Growth in this market is mainly driven by factors such ...

Austria Cardiac Rhythm Management Devices Market Outlook to 2022

Austria Cardiac Rhythm Management Devices Market Outlook to 2022

  • $ 4995
  • Industry report
  • September 2016
  • by Global Data

Austria Cardiac Rhythm Management Devices Market Outlook to 2022 Summary GlobalData’s new report, Austria Cardiac Rhythm Management Devices Market Outlook to 2022, provides key market data on the Austria ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.